Euroopa Liit - eesti - EMA (European Medicines Agency)

regeneron uk limited - rilonacept - cryopyrin-associated perioodilised sündroomid - immunosupressandid - rilonacept regeneron näitab tõsised sümptomid, sealhulgas perekondliku külma auto-põletikuline sündroomi (fcas) ja muckle-wells sündroomi (mws), cryopyrin seotud perioodiliste sündroomide (caps) raviks täiskasvanutel ja lastel vanuses 12 aastat ja vanemate.

Eesti - eesti - Ravimiamet

roche eesti osaühing - alfa-2a-interferoon - süstelahus - 9000000rÜ 0.5ml 12tk; 9000000rÜ 0.5ml 1tk; 9000000rÜ 0.5ml 6tk; 9000000rÜ 0.5ml 5tk

Eesti - eesti - Ravimiamet

roche eesti osaühing - alfa-2a-interferoon - süstelahus - 3000000rÜ 0.5ml 12tk; 3000000rÜ 0.5ml 5tk

Eesti - eesti - Ravimiamet

roche pharma ag - alfa-2a-interferoon - süstelahus - 3miljtÜ 0.5ml 0.5ml 30tk; 3miljtÜ 0.5ml 0.5ml 1tk

Eesti - eesti - Ravimiamet

roche pharma ag - alfa-2a-interferoon - süstelahus süstlis - 3miljtÜ 0.5ml 0.5ml 6tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

regeneron ireland designated activity company (dac) - cemiplimab - kartsinoom, squamous cell - antineoplastilised ained - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Eesti - eesti - Ravimiamet

norbrook laboratories limited - imidaklopriid - täpilahus - 40mg 0.4ml 1tk; 40mg 0.4ml 6tk; 40mg 0.4ml 24tk; 40mg 0.4ml 3tk

Eesti - eesti - Ravimiamet

norbrook laboratories limited - imidaklopriid - täpilahus - 80mg 0.8ml 4tk; 80mg 0.8ml 3tk; 80mg 0.8ml 24tk; 80mg 0.8ml 1tk

Eesti - eesti - Ravimiamet

norbrook laboratories limited - imidaklopriid - täpilahus - 400mg 4ml 3tk; 400mg 4ml 24tk; 400mg 4ml 1tk; 400mg 4ml 6tk; 400mg 4ml 4tk

Eesti - eesti - Ravimiamet

norbrook laboratories limited - imidaklopriid - täpilahus - 100mg 1ml 24tk; 100mg 1ml 1tk; 100mg 1ml 3tk; 100mg 1ml 6tk; 100mg 1ml 4tk